"Global Neurodegenerative Disease Market Overview:
Global Neurodegenerative Disease Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Neurodegenerative Disease Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Neurodegenerative Disease involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Neurodegenerative Disease Market:
The Neurodegenerative Disease Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Neurodegenerative Disease Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Neurodegenerative Disease Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Neurodegenerative Disease market has been segmented into:
Parkinson\'s Disease
Alzheimer\'s Disease
Multiple Sclerosis
Huntington Disease
and Other Indication Types
By Application, Neurodegenerative Disease market has been segmented into:
N-methyl-D-aspartate Receptor antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
and Other Drug Types
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Neurodegenerative Disease market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Neurodegenerative Disease market.
Top Key Players Covered in Neurodegenerative Disease market are:
Abbvie Inc.
Amneal Pharmaceuticals Inc.
Boehringer Ingelheim International Gmbh
F. Hoffmann-La Roche
Merck & Co. Inc.
among others.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Neurodegenerative Disease Market by Type
4.1 Neurodegenerative Disease Market Snapshot and Growth Engine
4.2 Neurodegenerative Disease Market Overview
4.3 Parkinson\'s Disease
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Parkinson\'s Disease: Geographic Segmentation Analysis
4.4 Alzheimer\'s Disease
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Alzheimer\'s Disease: Geographic Segmentation Analysis
4.5 Multiple Sclerosis
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Multiple Sclerosis: Geographic Segmentation Analysis
4.6 Huntington Disease
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Huntington Disease: Geographic Segmentation Analysis
4.7 and Other Indication Types
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 and Other Indication Types: Geographic Segmentation Analysis
Chapter 5: Neurodegenerative Disease Market by Application
5.1 Neurodegenerative Disease Market Snapshot and Growth Engine
5.2 Neurodegenerative Disease Market Overview
5.3 N-methyl-D-aspartate Receptor antagonists
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 N-methyl-D-aspartate Receptor antagonists: Geographic Segmentation Analysis
5.4 Cholinesterase Inhibitors
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Cholinesterase Inhibitors: Geographic Segmentation Analysis
5.5 Dopamine Agonists
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Dopamine Agonists: Geographic Segmentation Analysis
5.6 Immunomodulatory Drugs
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Immunomodulatory Drugs: Geographic Segmentation Analysis
5.7 and Other Drug Types
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 and Other Drug Types: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Neurodegenerative Disease Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ABBVIE INC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 AMNEAL PHARMACEUTICALS INC.
6.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
6.5 F. HOFFMANN-LA ROCHE
6.6 AND MERCK & CO. INC.
6.7 AMONG OTHERS.
Chapter 7: Global Neurodegenerative Disease Market By Region
7.1 Overview
7.2. North America Neurodegenerative Disease Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Parkinson\'s Disease
7.2.4.2 Alzheimer\'s Disease
7.2.4.3 Multiple Sclerosis
7.2.4.4 Huntington Disease
7.2.4.5 and Other Indication Types
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 N-methyl-D-aspartate Receptor antagonists
7.2.5.2 Cholinesterase Inhibitors
7.2.5.3 Dopamine Agonists
7.2.5.4 Immunomodulatory Drugs
7.2.5.5 and Other Drug Types
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Neurodegenerative Disease Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Parkinson\'s Disease
7.3.4.2 Alzheimer\'s Disease
7.3.4.3 Multiple Sclerosis
7.3.4.4 Huntington Disease
7.3.4.5 and Other Indication Types
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 N-methyl-D-aspartate Receptor antagonists
7.3.5.2 Cholinesterase Inhibitors
7.3.5.3 Dopamine Agonists
7.3.5.4 Immunomodulatory Drugs
7.3.5.5 and Other Drug Types
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Neurodegenerative Disease Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Parkinson\'s Disease
7.4.4.2 Alzheimer\'s Disease
7.4.4.3 Multiple Sclerosis
7.4.4.4 Huntington Disease
7.4.4.5 and Other Indication Types
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 N-methyl-D-aspartate Receptor antagonists
7.4.5.2 Cholinesterase Inhibitors
7.4.5.3 Dopamine Agonists
7.4.5.4 Immunomodulatory Drugs
7.4.5.5 and Other Drug Types
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Neurodegenerative Disease Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Parkinson\'s Disease
7.5.4.2 Alzheimer\'s Disease
7.5.4.3 Multiple Sclerosis
7.5.4.4 Huntington Disease
7.5.4.5 and Other Indication Types
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 N-methyl-D-aspartate Receptor antagonists
7.5.5.2 Cholinesterase Inhibitors
7.5.5.3 Dopamine Agonists
7.5.5.4 Immunomodulatory Drugs
7.5.5.5 and Other Drug Types
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Neurodegenerative Disease Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Parkinson\'s Disease
7.6.4.2 Alzheimer\'s Disease
7.6.4.3 Multiple Sclerosis
7.6.4.4 Huntington Disease
7.6.4.5 and Other Indication Types
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 N-methyl-D-aspartate Receptor antagonists
7.6.5.2 Cholinesterase Inhibitors
7.6.5.3 Dopamine Agonists
7.6.5.4 Immunomodulatory Drugs
7.6.5.5 and Other Drug Types
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Neurodegenerative Disease Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Parkinson\'s Disease
7.7.4.2 Alzheimer\'s Disease
7.7.4.3 Multiple Sclerosis
7.7.4.4 Huntington Disease
7.7.4.5 and Other Indication Types
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 N-methyl-D-aspartate Receptor antagonists
7.7.5.2 Cholinesterase Inhibitors
7.7.5.3 Dopamine Agonists
7.7.5.4 Immunomodulatory Drugs
7.7.5.5 and Other Drug Types
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Neurodegenerative Disease Scope:
|
Report Data
|
Neurodegenerative Disease Market
|
|
Neurodegenerative Disease Market Size in 2025
|
USD XX million
|
|
Neurodegenerative Disease CAGR 2025 - 2032
|
XX%
|
|
Neurodegenerative Disease Base Year
|
2024
|
|
Neurodegenerative Disease Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Abbvie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International Gmbh, F. Hoffmann-La Roche, and Merck & Co. Inc., among others..
|
|
Key Segments
|
By Type
Parkinson\'s Disease
Alzheimer\'s Disease
Multiple Sclerosis
Huntington Disease
and Other Indication Types
By Applications
N-methyl-D-aspartate Receptor antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
and Other Drug Types
|
